公开(公告)号：US11634404B2

公开(公告)日：2023-04-25

申请号：US16093365

申请日：2017-04-14

Applicant: The United States of America, as represented by the Secretary, Department of Health and Human Services ,  The University of Kansas ,  The University of North Carolina at Chapel Hill

Inventor： David R. Sibley ,  Amy Elizabeth Moritz ,  R. Benjamin Free ,  Joseph P. Steiner ,  Noel Terrence Southall ,  Marc Ferrer ,  Xin Hu ,  Warren S. Weiner ,  Jeffrey Aubé ,  Kevin Frankowski

IPC: C07D401/12 ,  A61P25/28 ,  C07D295/185 ,  C07D209/42 ,  C07D213/65 ,  C07D213/81 ,  C07D235/24 ,  C07D307/85 ,  C07D317/64 ,  C07D333/70 ,  C07D405/12 ,  C07D409/12 ,  C07D471/04

Abstract: The disclosure of a compound of Formula (I) or a pharmaceutically acceptable salt thereof (I) The variables W, R1, R2, R3, and R4 are defined in the disclosure. The disclosure provides a compound or salt of Formula (I) together with a pharmaceutically acceptable carrier. The disclosure also provides methods of treating a patient for Parkinson's disease and related syndromes, dyskinesia, especially dyskinesias secondary to treating Parkinson's disease with L-DOPA, neurodegenerative disorders such as Alzheimer's disease and dementia, Huntington's disease, restless legs syndrome, bipolar disorder and depression, schizophrenia, cognitive dysfunction, or substance use disorders, the methods comprising administering a compound of Formula I or salt thereof to the patient. The disclosure provides combination methods of treatment in which the compound of Formula (I) is administered to the patient together with one or more additional active agents.

公开(公告)号：US11241436B2

公开(公告)日：2022-02-08

申请号：US16480885

申请日：2018-01-25

Applicant: Northwestern University ,  The United States of America,as represented by the Secretary,Department of Health and Human Services ,  University of Kansas

Inventor： Congcong He ,  Sui Huang ,  Chen Wang ,  Altea Rocchi ,  Juan Jose Marugan ,  Marc Ferrer ,  Samarjit Patnaik ,  Yuchi Chen ,  Kevin Frankowski ,  Frank J. Schoenen

IPC: A61K31/519 ,  A61P25/30 ,  A61K31/704

Abstract: The invention provides a compound of formula (I): wherein R1, R2, R3, and R4 are as defined herein, ginsenoside Rg2 of structure (II): or a combination thereof, for use in treating or preventing a condition responsive to the induction of autophagy in a brain of a mammal in need thereof.

公开(公告)号：US09663521B2

公开(公告)日：2017-05-30

申请号：US14364759

申请日：2012-12-17

Applicant: THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES ,  UNIVERSITY OF KANSAS ,  NORTH-WESTERN UNIVERSITY

Inventor： Kevin Frankowski ,  Samarjit Patnaik ,  Sui Huang ,  Juan Jose Marugan ,  John Norton ,  Frank J. Schoenen ,  Noel Terrence Southall ,  Steven Titus ,  Wei Zheng

IPC: C07D487/04 ,  A61K31/519 ,  A61K31/695 ,  A61K45/06 ,  C07F7/18 ,  A61P35/02 ,  A61P35/04

CPC classification number: C07D487/04 ,  A61K31/519 ,  A61K31/695 ,  A61K45/06 ,  C07F7/1804

Abstract: The disclosure provides compounds for reducing the prevalence of the perinucleolar compartment in cells, for example, of formula (I), wherein R1, R2, R3, and R4 are as defined herein, that are useful in treating a disease or disorder associated with increased prevalence of the perinucleolar compartment, such as cancer. Also disclosed is a composition containing a pharmaceutically acceptable carrier and at least one compound embodying the principles of the invention, and a method of treating or preventing cancer in a mammal.

公开(公告)号：US20210323941A1

公开(公告)日：2021-10-21

申请号：US16093365

申请日：2017-04-14

Applicant: The United States of America, as represented by the Secretary, Department of Health and Human ,  The University of Kansas

Inventor： David R. Sibley ,  Amy Elizabeth Moritz ,  R. Benjamin Free ,  Joseph P. Steiner ,  Noel Terrence Southall ,  Marc Ferrer ,  Xin Hu ,  Warren S. Weiner ,  Jeffrey Aubé ,  Kevin Frankowski

IPC: C07D401/12 ,  C07D209/42 ,  C07D471/04 ,  C07D409/12 ,  C07D235/24 ,  C07D405/12 ,  C07D295/185 ,  C07D213/65 ,  C07D213/81 ,  C07D317/64 ,  C07D307/85 ,  C07D333/70 ,  A61P25/28

Abstract: The disclosure of a compound of Formula (I) or a pharmaceutically acceptable salt thereof (I) The variables W, R1, R2, R3, and R4 are defined in the disclosure. The disclosure provides a compound or salt of Formula (I) together with a pharmaceutically acceptable carrier. The disclosure also provides methods of treating a patient for Parkinson's disease and related syndromes, dyskinesia, especially dyskinesias secondary to treating Parkinson's disease with L-DOPA, neurodegenerative disorders such as Alzheimer's disease and dementia, Huntington's disease, restless legs syndrome, bipolar disorder and depression, schizophrenia, cognitive dysfunction, or substance use disorders, the methods comprising administering a compound of Formula I or salt thereof to the patient. The disclosure provides combination methods of treatment in which the compound of Formula (I) is administered to the patient together with one or more additional active agents.

公开(公告)号：US20170260192A1

公开(公告)日：2017-09-14

申请号：US15606740

申请日：2017-05-26

Applicant: The United States of America, as represented by the Secretary, Dept of Health and Human Services ,  University of Kansas ,  Northwestern University

Inventor： Kevin Frankowski ,  Samarjit Patnaik ,  Sui Huang ,  Juan Jose Marugan ,  John Norton ,  Frank J. Schoenen ,  Noel Terrence Southall ,  Steven Titus ,  Wei Zheng

IPC: C07D487/04 ,  C07F7/18 ,  A61K45/06 ,  A61K31/519 ,  A61K31/695

CPC classification number: C07D487/04 ,  A61K31/519 ,  A61K31/695 ,  A61K45/06 ,  C07F7/1804

Abstract: The disclosure provides compounds for reducing the prevalence of the perinucleolar compartment in cells, for example, of formula (I), wherein R1, R2, R3, and R4 are as defined herein, that are useful in treating a disease or disorder associated with increased prevalence of the perinucleolar compartment, such as cancer. Also disclosed is a composition containing a pharmaceutically acceptable carrier and at least one compound embodying the principles of the invention, and a method of treating or preventing cancer in a mammal.

公开(公告)号：US20230312511A1

公开(公告)日：2023-10-05

申请号：US18111241

申请日：2023-02-17

Applicant: The United States of America, as represented by the Secretary, Department of Health and Human ,  The University of Kansas ,  The University of North Carolina at Chapel Hill

Inventor： David R. Sibley ,  Amy Elizabeth Moritz ,  R. Benjamin Free ,  Joseph P. Steiner ,  Noel Terrence Southall ,  Marc Ferrer ,  Xin Hu ,  Warren S. Weiner ,  Jeffrey Aubé ,  Kevin Frankowski

IPC: C07D401/12 ,  A61P25/28 ,  C07D209/42 ,  C07D213/65 ,  C07D213/81 ,  C07D235/24 ,  C07D295/185 ,  C07D307/85 ,  C07D317/64 ,  C07D333/70 ,  C07D405/12 ,  C07D409/12 ,  C07D471/04

CPC classification number: C07D401/12 ,  A61P25/28 ,  C07D209/42 ,  C07D213/65 ,  C07D213/81 ,  C07D235/24 ,  C07D295/185 ,  C07D307/85 ,  C07D317/64 ,  C07D333/70 ,  C07D405/12 ,  C07D409/12 ,  C07D471/04

Abstract: The disclosure of a compound of Formula I or a pharmaceutically acceptable salt thereof




The variables W, R1, R2, R3, and R4 are defined in the disclosure. The disclosure provides a compound or salt of Formula I together with a pharmaceutically acceptable carrier. The disclosure also provides methods of treating a patient for Parkinson's disease and related syndromes, dyskinesia, especially dyskinesias secondary to treating Parkinson's disease with L-DOPA, neurodegenerative disorders such as Alzheimer's disease and dementia, Huntington's disease, restless legs syndrome, bipolar disorder and depression, schizophrenia, cognitive dysfunction, or substance use disorders, the methods comprising administering a compound of Formula I or salt thereof to the patient. The disclosure provides combination methods of treatment in which the compound of Formula I is administered to the patient together with one or more additional active agents.

公开(公告)号：US20210040074A1

公开(公告)日：2021-02-11

申请号：US16977897

申请日：2019-03-06

Applicant: David R. Sibley ,  Kathryn D. Luderman ,  Jennie L. Conroy ,  R. Benjamin Free ,  Prashi Jain ,  Noel T. Southall ,  Marc Ferrer ,  Jeffrey Aubé ,  Kevin Frankowski ,  The United States of America,as represented by the Secretary,Department of Health and Human Service ,  University of Kansas ,  The University of North Carolina at Chapel Hill

Inventor： David R. Sibley ,  Kathryn D. Luderman ,  Jennie L. Conroy ,  R. Benjamin Free ,  Prashi Jain ,  Noel T. Southall ,  Marc Ferrer ,  Jeffrey Aubé ,  Kevin Frankowski

IPC: C07D409/12 ,  C07D471/04

Abstract: Disclosed are compounds of formulas (I) and (III) for treating or preventing a disease or disorder responsive to activation of a D1 dopamine receptor agonist in a mammal in need thereof, wherein m, n, R1-R6, and R11-R13 are as defined herein. Examples of such disease or disorder include Alzheimer's Disease, schizophrenia, Parkinson's disease, a dyskinesia, and Huntington's disease.

公开(公告)号：US10301314B2

公开(公告)日：2019-05-28

申请号：US15606740

申请日：2017-05-26

Applicant: The United States of America, as represented by the Secretary, Department of Health and Human Services ,  University of Kansas ,  Northwestern University

Inventor： Kevin Frankowski ,  Samarjit Patnaik ,  Sui Huang ,  Juan Jose Marugan ,  John Norton ,  Frank J. Schoenen ,  Noel Terrence Southall ,  Steven Titus ,  Wei Zheng ,  Chen Wang

IPC: A61K31/519 ,  A61P35/04 ,  C07D487/04 ,  C07F7/18 ,  A61K31/695 ,  A61K45/06

Abstract: The disclosure provides compounds for reducing the prevalence of the perinucleolar compartment in cells, for example, of formula (I), wherein R1, R2, R3, and R4 are as defined herein, that are useful in treating a disease or disorder associated with increased prevalence of the perinucleolar compartment, such as cancer. Also disclosed is a composition containing a pharmaceutically acceptable carrier and at least one compound embodying the principles of the invention, and a method of treating or preventing cancer in a mammal.

公开(公告)号：US20170260141A1

公开(公告)日：2017-09-14

申请号：US15529290

申请日：2015-11-25

Applicant: University of Kansas

Inventor： Jeffrey Aube ,  Kevin Frankowski ,  Thomas Prisinzano ,  Laura Bohn

IPC: C07D217/08 ,  C07D223/16 ,  C07D209/44

CPC classification number: C07D217/08 ,  C07D209/44 ,  C07D223/16

Abstract: The present technology is directed to compounds, compositions, and methods related to non-morphinan-like kappa opioid receptor (KOR) antagonists. The technology is suited to treat addiction, diuresis, depression, post traumatic stress disorder, an eating disorder, panic disorder, social anxiety disorder, general anxiety disorder, obsessive compulsive disorders, excessive or unreasonable specific phobias, and/or other conditions related to anxiety or aversion-reward responses.

公开(公告)号：US12145922B2

公开(公告)日：2024-11-19

申请号：US18111241

申请日：2023-02-17

Applicant: The United States of America, as represented by the Secretary, Department of Health and Human Services ,  The University of Kansas ,  The University of North Carolina at Chapel Hill

Inventor： David R. Sibley ,  Amy Elizabeth Moritz ,  R. Benjamin Free ,  Joseph P. Steiner ,  Noel Terrence Southall ,  Marc Ferrer ,  Xin Hu ,  Warren S. Weiner ,  Jeffrey Aubé ,  Kevin Frankowski

IPC: C07D401/12 ,  A61P25/28 ,  C07D209/42 ,  C07D213/65 ,  C07D213/81 ,  C07D235/24 ,  C07D295/185 ,  C07D307/85 ,  C07D317/64 ,  C07D333/70 ,  C07D405/12 ,  C07D409/12 ,  C07D471/04

Abstract: The disclosure of a compound of Formula I or a pharmaceutically acceptable salt thereof The variables W, R1, R2, R3, and R4 are defined in the disclosure. The disclosure provides a compound or salt of Formula I together with a pharmaceutically acceptable carrier. The disclosure also provides methods of treating a patient for Parkinson's disease and related syndromes, dyskinesia, especially dyskinesias secondary to treating Parkinson's disease with L-DOPA, neurodegenerative disorders such as Alzheimer's disease and dementia, Huntington's disease, restless legs syndrome, bipolar disorder and depression, schizophrenia, cognitive dysfunction, or substance use disorders, the methods comprising administering a compound of Formula I or salt thereof to the patient. The disclosure provides combination methods of treatment in which the compound of Formula I is administered to the patient together with one or more additional active agents.